(Q36574341)

15 August 2017

1 reference

title

Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus (English)

1 reference

15 August 2017

Anton Stuetz

1

1 reference

15 August 2017

Karl Baumann

2

1 reference

15 August 2017

Maximilian Grassberger

3

1 reference

15 August 2017

Klaus Wolff

4

1 reference

15 August 2017

Josef G Meingassner

5

1 reference

15 August 2017

publication date

22 August 2006

1 reference

International Archives of Allergy and Immunology

15 August 2017

published in

1 reference

15 August 2017

volume

141

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

199-212

1 reference

Atopic dermatitis: new insights and opportunities for therapeutic intervention

15 August 2017

cites work

1 reference

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells

21 January 2018

1 reference

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

21 January 2018

1 reference

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils

21 January 2018

1 reference

Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids

21 January 2018

1 reference

Pimecrolimus does not affect Langerhans cells in murine epidermis

21 January 2018

1 reference

Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells

21 January 2018

1 reference

Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis

21 January 2018

1 reference

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus

21 January 2018

1 reference

Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A.

21 January 2018

1 reference

Pimecrolimus: a review of its use in atopic dermatitis

21 January 2018

1 reference

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

21 January 2018

1 reference

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

21 January 2018

1 reference

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

21 January 2018

1 reference

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

21 January 2018

1 reference

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

21 January 2018

1 reference

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

21 January 2018

1 reference

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

21 January 2018

1 reference

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

21 January 2018

1 reference

Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study

21 January 2018

1 reference

Repigmentation of vitiligo with pimecrolimus cream: a case report

21 January 2018

1 reference

Pimecrolimus -- an anti-inflammatory drug targeting the skin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000095289

1 reference

15 August 2017

1 reference